Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy responseShengshan Xu, Zhuming Lu, Min Ye et al.|BMC Cancer|2024Cited by 50
Multi‑omics identification of a signature based on malignant cell-associated ligand–receptor genes for lung adenocarcinomaShengshan Xu, Zhuming Lu, Xiguang Chen et al.|BMC Cancer|2024Cited by 36
Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2Shengshan Xu, Yuchen Liu, Xiguang Chen et al.|Frontiers in Immunology|2023Cited by 26
Comparison of pembrolizumab plus chemotherapy versus concurrent or sequential radiochemotherapy in patients with driver mutation-lacking lung adenocarcinoma presenting with recurrent laryngeal nerve invasion leading to hoarseness.Zhuming Lu, Zhihui Wang, Guoping Xiong et al.|Journal of Clinical Oncology|2024Cited by 10